Combination immunotherapy and chemotherapy for advanced colorectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates a novel treatment approach for patients with refractory metastatic colorectal cancer that is mismatch-repair proficient or microsatellite stable. It involves an initial combination of Pembrolizumab and a dendritic cell vaccine to stimulate the immune response, followed by maintenance therapy with Trifluridine/Tipiracil and Bevacizumab. The study aims to assess both the clinical efficacy and immunological activity of this sequential treatment strategy. The trial is single-arm and open-label, conducted across multiple centers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Be willing and able to provide written informed consent.
* Histologically confirmed pMMR or MSS mCRC
* Male or female, aged ≥ 18 years
* Life expectancy greater than 12 weeks
* ECOG performance status \<2
* Patient suitable for the collection of biological material from leukapheresis: negative serological tests (HIV, HBV, HCV, Treponema pallidum); normal cardiological parameters (12-lead ECG and echocardiogram); evaluation by transfusionist to exclude possible contraindications to leukapheresis; recovered (grade 1 or less by CTCAE 5.0) from all the adverse events related to previous treatments.Exclusion Criteria:
* Patients must have measurable disease by RECIST v 1.1 criteria on CT (or MRI) scan of the chest, abdomen and pelvis. See section 9.2 and Appendix D for the evaluation of measurable disease.
* Prior treatment with 1-2 chemotherapy regimens in an advanced setting, including (if not contraindicated) fluoropyrimidines, irinotecan, oxaliplatin, an anti-VEGF monoclonal antibody and/or anti-EGFR monoclonal antibody for RAS wild-type tumors.
* Patients must have normal organ and marrow function as defined below:

leukocytes \>3,000/μL, absolute neutrophil count \>1,500/μL, platelets \>100,000/μL, total bilirubin \< 1.5 X institutional upper limit of normal (ULN), AST(SGOT)/ALT(SGPT) \<2.5 X ULN, creatinine \< 1.5 X ULN OR creatinine clearance \>30 mL/min/1.73 m2

* The autologous surgical specimen needed for vaccine manufacturing must have been collected and sent to the Somatic Cell Therapy Lab of IRCCS IRST and must fulfill all the acceptance criteria prescribed by the GMP procedures
* Recovery (grade 1 or less by CTCAE 5.0) from all the adverse events related to previous surgery.
* A female participant is eligible to participate if she is not pregnant and not breastfeeding. Female patients of childbearing potential and all male patients must accept and be compliant with a highly effective contraceptive method
* Participant is willing and able to give informed consent for participation in the study.

Exclusion Criteria:

The participant may not enter the study if ANY of the following apply:

* Prior treatment with FTD/TPI for mCRC
* Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
* Participation in another clinical trial with any investigational agents within 30 days prior to study screening.
* Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to Pembrolizumab, FTD/TPI, Bevacizumab or components of the DC vaccine.
* History of congenital or acquired immunodeficiency, including history of organ transplantation.
* Any active inflammatory or autoimmune disease requiring systemic steroids or other immunomodulatory agents
* Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* Other known malignant neoplastic diseases in the patient's medical history with a disease-free interval of less than 5 years (except for previously treated basal cell carcinoma and in situ carcinoma of the uterine cervix).

Where it's running

• IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"-IRST S.r.l.
  Meldola, Forlì Cesena, Italy Recruiting
• Pia Fondazione di Culto e Religione Azienda Ospedaliera "Card.G.Panico"
  Tricase, Lecce, Italy Not yet recruiting

Study contacts

• Principal investigator: Alessandro Passardi — Irccs Irst
• Study coordinator: Oriana Nanni
• Email: oriana.nanni@irst.emr.it
• Phone: 0543739266

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ABT-301 with tislelizumab and bevacizumab for pMMR/non‑MSI‑H advanced or metastatic colorectal cancer

  This trial will test whether adding the oral drug ABT-301 to fixed-dose tislelizumab and bevacizumab is safe and tolerable for adults with pMMR/non‑MSI‑H locally advanced or metastatic colorectal cancer who have had at least two prior systemic therapies.

  Recruiting Phase 1/2 Anbogen Therapeutics, Inc. · Liverpool, New South Wales and 14 other locations · NCT07244705

• Sacituzumab tirumotecan plus pembrolizumab as first-line maintenance for metastatic cervical cancer

  This trial tests whether adding the antibody-drug conjugate sacituzumab tirumotecan to pembrolizumab (with or without bevacizumab) as maintenance treatment can help people with metastatic cervical cancer live longer or keep the cancer from growing.

  Recruiting at 191 sites Phase 3 Merck Sharp & Dohme LLC · Birmingham, Alabama and 190 other locations · NCT07216703

• Adding bevacizumab to carboplatin, paclitaxel and pembrolizumab for pMMR, TP53‑mutated advanced or recurrent endometrial cancer

  This trial tests whether adding bevacizumab to carboplatin and paclitaxel with pembrolizumab helps people with pMMR, TP53‑mutated advanced or recurrent endometrial cancer live longer without the disease getting worse.

  Recruiting at 308 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 308 other locations · NCT07198074

• BL-B01D1 plus pembrolizumab, with or without bevacizumab, for recurrent or metastatic cervical and endometrial cancer

  This trial will try a combination of BL-B01D1 and pembrolizumab, with or without bevacizumab, in adults with recurrent or metastatic cervical or endometrial cancer to see if it shrinks tumors or controls the disease.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT07054567

• ctDNA-guided choice of cetuximab versus bevacizumab with trifluridine/tipiracil for RAS/BRAF wild-type metastatic colorectal cancer

  This trial tests whether a ctDNA blood test can help choose cetuximab plus trifluridine/tipiracil versus bevacizumab plus trifluridine/tipiracil for people with RAS/BRAF wild-type metastatic colorectal cancer who have progressed after prior treatments.

  Recruiting Phase 1/2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07012954

• Comparing two treatments for advanced colorectal cancer

  This study is testing whether a combination of two cancer treatments works better than another combination for people with advanced colorectal cancer that hasn’t responded to other therapies.

  Recruiting Phase 3 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT06992648

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.